The unsolicited takeover offer

No thanks we're good...                                                                                                                                                                                                                                                                                                                                                                                                                 March 15, 2023 | [Read Online]( Good day, 360 – Here are our top trading ideas to watch today – plus our TOP headlines for today, the ides of March. Be the best prepared trader on the Street! JNCE - Up over 34% after unsolicited takeover offer HUBC - 15% higher in pre-market after receiving $4 million from PIPE investors at $10 per share SMAR - 12% higher in pre-market after earnings beat *A message from BioTech Stock Trends [🔥 Hot Stock of the Day 🔥]( This [microcap biotech stock]( could be just what the doctor ordered right now. They have a pipeline of technologies to tackle neurodegenerative and infectious diseases, we’re talking major efforts like Alzheimer’s and Parkinson’s. They just got the FDA greenlight to go ahead with a Phase 2a Parkinson’s drug trial. The technical indicators don’t get much better looking than this either… And get this, the latest filing showed that the company is sitting on a pile of cash worth more than the value of the whole company right now! 💰 The company just had a [game-changing announcement from the FDA]( last week, and while the stock is definitely on the uptrend since then, most traders are not remotely aware of the opportunity here. [Learn more about this little firecracker]( that is trading just under $1 right now. 🧨 Don’t spend too much time in the waiting room though….this stock has a [history of fast moves](. The next leg up may be here and gone before you know it! *Sponsored by Lifewater Media, see disclosures below JNCE - Up over 34% after unsolicited takeover offer Jounce Therapeutics (JNCE) confirmed late yesterday the receipt of an unsolicited proposal from Concentra Biosciences to acquire 100% of the company for $1.80 per share subject to diligence and availability of at least $130 million of cash and equivalents at closing. The stock is gapping 34% higher in pre-market trading around $1.47 still lower than the proposal. The market is now pricing in the likelihood of the takeover going through. Additionally, now that the company is a takeover target there is also the possibility of another bidder stepping in at still higher prices. Of course, the deal could also fall through. $1.40 was resistance in the after-hours and has acted as support in the pre-market so that should be an important pivot point. Above $1.40, targets to the upside are $1.50 and then the pre-market high of $1.56. Above that, technically there is no resistance until the proposed takeover price of $1.80. Above $1.80 the next target is $2, with $2.20 and $2.30 above that. Below $1.40, there is potential support at $1.27, then $1.23, with a gap to fill at $1.06. HUBC - 15% higher in pre-market after receiving $4 million from PIPE investors at $10 per share Hub Cyber Security (HUBC) announced that it had issued and sold approximately 400,00 shares to two of the original PIPE investors at a price of $10 per share for $4million in proceeds in a private placement. The shares were sold pursuant to the original PIPE terms entered into the company’s business combination. Remaining PIPE funds are currently being negotiated with investors and the company remains in discussion with the investors to receive those funds. This is a SPAC that was done at $10 and completed it’s reverse merger. However the stock is now trading below $2 as the market deemed many SPAC’s overpriced at $10. However, it is good news that original investors are upholding their contractual agreements and are investing at the company at $10 much higher than the current stock price. This could add confidence to the name and lead to a push higher from here as new investors have the opportunity to invest at still much lower prices than original PIPE investors. The $1.95-$2 area has been resistance in after-hours and the pre-market and should be an important pivot point moving forward. Above $2, the first target for bulls is $2.04 which is the after-hours high. Above that targets to the upside are $2.50, $2.69 and then there is blue sky for the newly listed reverse merger stock. Below $1.95, there is potential support at $1.70-$1.75. Further targets to the downside are a gap fill to $1.67 and then $1.50. SMAR - 12% higher in pre-market after earnings beat Smartsheet (SMAR) reported Q4 EPS of $0.07 vs the -$0.01 estimate. Revenue came in at $212.3 million vs the $206.25 million estimate. SMAR also guided Full year 2024 EPS of $0.31 to $0.38 versus the consensus of -$0.09. The market expected SMAR to be losing money last quarter and for the full year this year. SMAR surprised with positive EPS and guidance that had investors cheering, and the stock is up 12% this morning on the news. $43.30 was resistance in the after-hours and should be an important pivot point going forward. Above it is the pre-market high at $43.50 with targets at $44, $45 and $46 higher. Below $43.30, there is potential support at $41.50, with $41, $40.50 and $38.30 below that. Economic Calendar (EST) 7:00am Mortgage applications 8:30am PPI- Final 8:30am Retail sales 8:30am Empire state Mfg Index 10:00am Business Inventories 10:00am Housing market index 10:30am Petroleum report 👉 No Fed speakers scheduled Earnings for Today (After Market) ADBE, AMRS, ARRY, AVGR, BOXL, BRLT, CAPR, CDRE, CPRX, CYN, EVCM, FIVE, FLNT, FNV, FSM, GRPN, GRWG, HLTH, HSAI, ISPO, LEGH, LIDR, MGNX, MLYS, MTNB, MXCT, NATR, NC, NWPX, OTRK, OWLT, PANL, PATH, PD, PKOH, SENS, SGC, SMR, SSSS, TBLT, TKNO, TPC, VNRX, VXRT, YY, ZOM, ZTO Top Headlines SNSE: Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023 VINC: Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023 CRVS: Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting SNTI: Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting CRBP: Corbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting CGEM: Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting NMRK Newmark Raises $500 Million for Programmatic Joint Venture for Castle Park Investments GM GM extends production halt at Mexico truck plant over supply chain issue. INPX Inpixon Completes Distribution and Business Combination of CXApp Holding Corp. with KINS Technology Group Inc. MSFT maintains dividend at $0.68/shr TikTok’s leadership is discussing the possibility of separating from its Chinese parent company to help address concerns about national security risks – Bloomberg PFE FDA authorizes Pfizer's Covid omicron booster as fourth shot for kids under 5 ETON: Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600 OBSV: ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023 STOK Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome IDEX: Ideanomics subsidiary Energica announces new partnerships to develop all-electric solutions for aviation CEMI: Chembio Announces Letter to Stockholders Regarding Tender Offer GENI: Genius Sports Showcases Second Spectrum Technology in Visual Product Demonstration BTCM: BIT Mining Announces Sale of Remaining Shares of Crypto Flow Technology Limited JAZZ Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline ASPI ASP Isotopes Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules USO WTI oil drops below $70 a barrel for first time since December 2021. OTLY Oatly Announces Financing Commitments of $425 Million CGTX: Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD IXHL: Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment CNTX: Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 PTGX Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera GNRC: Generac Introduces the GS100 Solar Panel for Off-Grid Charging of the Company's Portable Battery Stations NOTE: FiscalNote Selected by Georgia Legislature, Lieutenant Governor, and Dekalb County Board Commissioners to Enhance Constituent Engagements and Communications To Your Success! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions DISCLAIMER: To more fully understand RagingBull.com, LLC’s issuer-paid advertisement disclaimer and disclosure policy located at [(. *PAID ADVERTISEMENT. RagingBull has been paid fifteen thousand dollars via ach bank transfer by Lifewater Media for advertising Inhibikase Therapeutics from a period beginning on March 15, 2023 through March 16 of the same year. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in Inhibikase Therapeutics. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Inhibikase Therapeutics, increased trading volume, and possibly an increased share price of the Inhibikase Therapeutics securities, which may or may not be temporary and decrease once the marketing arrangement has ended. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 lee, NH 03861, United States [[beehiiv logo]Powered by beehiiv](